0000899243-19-004864.txt : 20190226
0000899243-19-004864.hdr.sgml : 20190226
20190226160617
ACCESSION NUMBER: 0000899243-19-004864
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190222
FILED AS OF DATE: 20190226
DATE AS OF CHANGE: 20190226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ADELMAN DANIEL C MD
CENTRAL INDEX KEY: 0001222037
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 19633405
MAIL ADDRESS:
STREET 1: 23 WOODLEAF AVENUE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94061
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-22
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001222037
ADELMAN DANIEL C MD
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
Chief Medical Officer
Common Stock, $0.0001 par value
2019-02-22
4
A
0
11875
0.00
A
21250
D
Stock Option
(right to buy)
23.72
2019-02-22
4
A
0
71250
0.00
A
2029-02-22
Common Stock
71250
71250
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney in Fact for Daniel C. Adelman
2019-02-26